Gilead Sciences (NASDAQ:GILD) Price Target Raised to $165.00

Gilead Sciences (NASDAQ:GILD) had its price target lifted by analysts at Argus from $135.00 to $165.00 in a research note issued on Thursday,MarketScreener reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Argus’ target price indicates a potential upside of 8.28% from the company’s previous close.

Several other research analysts also recently weighed in on GILD. Wolfe Research lifted their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Cantor Fitzgerald lifted their target price on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Morgan Stanley raised their price target on shares of Gilead Sciences from $150.00 to $171.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Daiwa Securities Group increased their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Finally, Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $103.00 to $118.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 11th. Twenty-three research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $155.44.

Gilead Sciences Price Performance

Gilead Sciences stock traded up $1.27 during mid-day trading on Thursday, hitting $152.39. The company’s stock had a trading volume of 553,961 shares, compared to its average volume of 7,609,436. The stock has a market capitalization of $189.06 billion, a P/E ratio of 22.59, a P/E/G ratio of 2.03 and a beta of 0.36. Gilead Sciences has a twelve month low of $93.37 and a twelve month high of $157.29. The stock’s fifty day moving average price is $132.85 and its two-hundred day moving average price is $123.38. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same period last year, the company posted $1.90 EPS. The company’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current year.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the transaction, the insider owned 120,288 shares in the company, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00. Following the sale, the chief executive officer owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. The trade was a 16.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 319,891 shares of company stock valued at $45,091,556 over the last quarter. 0.27% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after acquiring an additional 2,113,692 shares during the period. State Street Corp increased its position in Gilead Sciences by 1.9% during the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock worth $7,393,921,000 after buying an additional 1,151,213 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Gilead Sciences by 2.6% in the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock valued at $3,231,548,000 after buying an additional 727,515 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Gilead Sciences by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after acquiring an additional 1,195,269 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after acquiring an additional 3,046,688 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.